. 2021 Mar 12;9(3):289. doi: 10.3390/biomedicines9030289

Table 3.

Univariate and multivariate survival analysis of clinicopathological factors and integrin α2β1.

		PFS				PFI				OS
	n	Log-Rank		MV Cox Regression		Log-Rank		MV Cox Regression		Log-Rank
		MS	p	HR (CI 95%)	p	MS	p	HR (CI 95%)	p	MS	p
Age ≤ 62 years	19	22	0.965			17	0.970			nr	0.193
Age > 62 years	23	22	0.965			17	0.970			42	0.193
<pT3c	7	27	0.665			22	0.679			45	0.928
pT3c	35	22	0.665			17	0.679			42	0.928
pN0	5	29	0.163			17	0.145			45	0.929
pN1	28	22	0.163			22	0.145			42	0.929
cM0	29	27				22				nr
cM1	13	16	0.081	2.06 (0.92–4.62)	0.081	11	0.068	2.10 (0.94–4.69)	0.072	30	0.015
G1/G2	2	14	0.579			8	0.610			30	0.843
G3	40	22	0.579			17	0.610			42	0.843
Ascites absent	6	35	0.147			30	0.139			42	0.408
Ascites present	36	19	0.147			15	0.139			38	0.408
MR Tumor absent	30	27				22				45
MR Tumor present	12	13	0.008	2.19 (1.03–4.68)	0.043	9	0.010	2.10 (0.99-4.51)	0.057	26	0.041
Integrin α2β1 low	27	29				25				45
Integrin α2β1 high	15	16	0.035	2.46 (1.14–5.29)	0.021	11	0.034	2.45 (1.14-5.26)	0.022	30	0.155

Legend: n: number of patients, Cox regression: multivariate Cox regression, MS: median survival (in months) in Kaplan–Meier estimator, HR: hazard ratio, CI: confidence interval, MR Tumor: macroscopic residual tumor; nr: median survival not reached.